MedTrace Logo

Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction

NCT03506412 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-02-04

Study results available
· View outcomes & findings →

Summary

To determine biomarker responses to Entresto™in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and who have high or low serum neprilysin (NEP) levels.

Conditions

Interventions

DRUG

Entresto™ 49Mg-51 mg tablet

Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Naveen L Pereira, MD · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-25
Primary Completion
2021-03-23
Completion
2021-03-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03506412 on ClinicalTrials.gov